Literature DB >> 20211249

Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs.

Yuval Samuni1, Hisanari Ishii, Fuminori Hyodo, Uri Samuni, Murali C Krishna, Sara Goldstein, James B Mitchell.   

Abstract

Geldanamycin (GM), a benzoquinone ansamycin antibiotic, is a natural product inhibitor of Hsp90 with potent and broad anti-cancer properties. Because of its adverse effects on liver, its less toxic derivatives 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) are currently being evaluated for the treatment of cancer. Previously, it has been demonstrated that the redox cycling of GM by NADPH-cytochrome P450 reductase leads to the formation of the GM semiquinone and superoxide radicals, the latter being identified using spin-trapping. We hypothesized that the different hepatotoxicity induced by GM, 17-AAG and 17-DMAG reflects the redox active properties of the quinone moiety and possibly the extent of superoxide formation, which may stimulate cellular oxidative injury. Our data demonstrate that superoxide can be efficiently trapped during the reduction of GM, 17-AAG and 17-DMAG by NADPH-cytochrome P450 reductase, and that superoxide formation rate followed the order 17-DMAG > 17-AAG > GM. In the absence of superoxide scavengers, the rate of NADPH oxidation followed the order 17-DMAG > GM > 17-AAG. The half-wave one-electron reduction potentials (E(1/2)) of GM, 17-AAG and 17-DMAG in DMSO have been determined to be -0.37, -0.13 and -0.015V (vs. Ag/AgCl), respectively. If the same order of E(1/2) follows in neutral aqueous media, thermodynamic considerations imply that 17-DMAG is more readily reduced by the P450 reductase as well as by superoxide. The order of the drug cytotoxicity toward rat primary hepatocytes, as determined by their effect on cell viability and on intracellular oxidant level, was opposite to the order of E(1/2) of the respective quinone/semiquinone couples. These results suggest that hepatotoxicity exhibited by the Hsp90 inhibitors belonging to benzoquinone ansamycins could be attributed to superoxide. The apparent discrepancy between the order of toxicity and the orders of superoxide formation rate, which is correlated with E(1/2), is discussed. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20211249      PMCID: PMC2862863          DOI: 10.1016/j.freeradbiomed.2010.03.001

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  25 in total

1.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

Authors:  Udai Banerji; Anne O'Donnell; Michelle Scurr; Simon Pacey; Sarah Stapleton; Yasmin Asad; Laura Simmons; Alison Maloney; Florence Raynaud; Maeli Campbell; Michael Walton; Sunil Lakhani; Stanley Kaye; Paul Workman; Ian Judson
Journal:  J Clin Oncol       Date:  2005-06-20       Impact factor: 44.544

2.  In vitro detection of differential and cell-specific hepatobiliary toxicity induced by geldanamycin and 17-allylaminogeldanamycin in rats.

Authors:  H P Behrsing; K Amin; C Ip; L Jimenez; C A Tyson
Journal:  Toxicol In Vitro       Date:  2005-08-02       Impact factor: 3.500

3.  Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition.

Authors:  L Whitesell; S D Shifrin; G Schwab; L M Neckers
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

4.  Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.

Authors:  Xueyu Chen; Robert R Bies; Ramesh K Ramanathan; Eleanor G Zuhowski; Donald L Trump; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2004-10-19       Impact factor: 3.333

Review 5.  Chemistry of peroxynitrites as compared to peroxynitrates.

Authors:  Sara Goldstein; Johan Lind; Gábor Merényi
Journal:  Chem Rev       Date:  2005-06       Impact factor: 60.622

6.  Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.

Authors:  Elizabeth R Glaze; Amy L Lambert; Adaline C Smith; John G Page; William D Johnson; David L McCormick; Alan P Brown; Barry S Levine; Joseph M Covey; Merrill J Egorin; Julie L Eiseman; Julianne L Holleran; Edward A Sausville; Joseph E Tomaszewski
Journal:  Cancer Chemother Pharmacol       Date:  2005-06-29       Impact factor: 3.333

7.  Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase.

Authors:  V G Brunton; G Steele; A D Lewis; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

8.  Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.

Authors:  M J Egorin; D M Rosen; J H Wolff; P S Callery; S M Musser; J L Eiseman
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

9.  Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide.

Authors:  M C Krishna; D A Grahame; A Samuni; J B Mitchell; A Russo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

10.  Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.

Authors:  J G Supko; R L Hickman; M R Grever; L Malspeis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more
  23 in total

1.  First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.

Authors:  Giovanna Speranza; Larry Anderson; Alice P Chen; Khanh Do; Michelle Eugeni; Marcie Weil; Larry Rubinstein; Eva Majerova; Jerry Collins; Yvonne Horneffer; Lamin Juwara; Jennifer Zlott; Rachel Bishop; Barbara A Conley; Howard Streicher; Joseph Tomaszewski; James H Doroshow; Shivaani Kummar
Journal:  Invest New Drugs       Date:  2017-08-12       Impact factor: 3.850

2.  Computational polypharmacology analysis of the heat shock protein 90 interactome.

Authors:  Andrew Anighoro; Dagmar Stumpfe; Kathrin Heikamp; Kristin Beebe; Leonard M Neckers; Jürgen Bajorath; Giulio Rastelli
Journal:  J Chem Inf Model       Date:  2015-02-23       Impact factor: 4.956

Review 3.  Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development.

Authors:  Len Neckers; Brian Blagg; Timothy Haystead; Jane B Trepel; Luke Whitesell; Didier Picard
Journal:  Cell Stress Chaperones       Date:  2018-02-01       Impact factor: 3.667

Review 4.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

5.  Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress.

Authors:  Peter M Scarbrough; Kranti A Mapuskar; David M Mattson; David Gius; Walter H Watson; Douglas R Spitz
Journal:  Free Radic Biol Med       Date:  2011-11-04       Impact factor: 7.376

6.  Differential impact of tetratricopeptide repeat proteins on the steroid hormone receptors.

Authors:  Jan-Philip Schülke; Gabriela Monika Wochnik; Isabelle Lang-Rollin; Nils Christian Gassen; Regina Theresia Knapp; Barbara Berning; Alexander Yassouridis; Theo Rein
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

7.  Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.

Authors:  David Hong; Rabih Said; Gerald Falchook; Aung Naing; Stacy Moulder; Apostolia-Maria Tsimberidou; Gerald Galluppi; Naveen Dakappagari; Chris Storgard; Razelle Kurzrock; Lee S Rosen
Journal:  Clin Cancer Res       Date:  2013-07-19       Impact factor: 12.531

Review 8.  Hsp90 molecular chaperone inhibitors: are we there yet?

Authors:  Len Neckers; Paul Workman
Journal:  Clin Cancer Res       Date:  2012-01-01       Impact factor: 12.531

9.  Involvement of calcium-mediated reactive oxygen species in inductive GRP78 expression by geldanamycin in 9L rat brain tumor cells.

Authors:  Fang-Chun Sun; Hsin-Yi Shyu; Meng-Shiou Lee; Meng-Shiunn Lee; Yiu-Kay Lai
Journal:  Int J Mol Sci       Date:  2013-09-18       Impact factor: 5.923

10.  Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells.

Authors:  Guozhu Chen; Xuhui Zhang; Ming Zhao; Yan Wang; Xiang Cheng; Di Wang; Yuanji Xu; Zhiyan Du; Xiaodan Yu
Journal:  BMC Cancer       Date:  2011-05-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.